

Retraction of the main papilla toward the biliary system in patients with primary sclerosing cholangitis

Erkan Parlak, Aydın Şeref Köksal, Selçuk Dişibeyaz, Bahattin Çiçek, Bülent Ödemiş, Nurgül Şaşmaz, Burhan Şahin
Department of Gastroenterology, Türkiye Yüksek İhtisas Hospital, Ankara, Turkey

ABSTRACT

Background/Aims: Retraction of the main papilla toward the biliary system was observed in 70% of patients with primary sclerosing cholangitis (PSC). However, this observation was confounded by the fact that all of the patients with this finding had a prior history of sphincterotomy. The aim of the present study was to observe whether main papillary retraction can be seen in patients with naïve papillae and accompanies the progression of the disease.

Materials and Methods: The study was conducted in a single tertiary reference center and included 4 patients with PSC.

Results: Main papillary retraction was seen to emerge with progression of PSC after an initial presentation with intra and extrahepatic involvement in 2 patients and after progression from intrahepatic to extrahepatic bile ducts in 1 patient. Main papillary retraction was seen in 2 patients with naïve papillae and could be detected by magnetic resonance cholangiography in 1 patient.

Conclusion: Retraction of the main papilla can be seen in patients with PSC regardless of prior sphincterotomy history.

Keywords: Primary sclerosing cholangitis, papilla, retraction, MRCP

INTRODUCTION

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts, leading to formation of multifocal bile duct strictures (1). While patients are initially often asymptomatic, they can eventually develop jaundice, pruritus and fever. Disease progression is slow and highly variable, but culminates in cirrhosis and complications related to portal hypertension. Problems more specific to PSC can also develop, such as recurrent ascending cholangitis and cholangiocarcinoma (2-4). A diagnosis of PSC is made in patients who have a cholestatic biochemical profile combined with multifocal bile duct strictures and segmental dilations on cholangiography when secondary causes of sclerosing cholangitis have been excluded (1,5)

In a previous study we showed that the main papilla was retracted away from the lumen of the duodenum toward the biliary system on endoscopy in 7 out of 10 patients with PSC (6). The remaining 3 patients without retraction had only intrahepatic involvement compared to those with retraction having both intra and extrahepatic involvement. We suggested that the presence of

main papillary retraction might be a useful sign in the diagnosis of PSC necessitating a different approach during ERCP. However all of the patients with main papillary retraction had a history of sphincterotomy therefore further observations were needed (7).

The primary aim of this study was to demonstrate whether main papillary retraction can be seen in patients with PSC who have not previously undergone endoscopic sphincterotomy. The secondary aim was to observe whether extrahepatic progression of PSC leads to main papillary retraction.

CASE PRESENTATIONS

Case 1: Progression of PSC accompanied by emergence of main papillary retraction

A 70-year-old man was admitted to our clinic with the complaint of itching in the last 1 year. Past medical history was insignificant. An ERCP was performed. The cholangiogram showed involvement of both of the intra and extrahepatic bile ducts. The main papilla did not appear to be retracted toward the biliary system (Figure 1a). Endoscopic sphincterotomy, balloon dilation and

Address for Correspondence: Aydın Şeref Köksal, Department of Gastroenterology, Türkiye Yüksek İhtisas Hospital, Ankara, Turkey
E-mail: koksalas@yahoo.com

Received: March 22, 2013

Accepted: December 02, 2013

© Copyright 2014 by The Turkish Society of Gastroenterology • Available online at www.turkjgastroenterol.org • DOI: 10.5152/tjg.2014.5238



Figure 1. a-c. The normal naïve papilla of a patient with intra and extrahepatic PSC (a). The papilla and the surrounding duodenal wall was retracted and got a tent-like appearance (arrow) 4.5 years later (b,c).

nasobiliary drainage provided symptomatic improvement. In 2009, 4.5 years after the first ERCP, the patient returned with acute cholangitis. The main papilla was seen to be retracted toward the biliary system at this time (Figure 1b, c). Balloon dilation and short-term nasobiliary drainage were performed. Brush cytology showed no malignancy.

Case 2: Progression of PSC to the extrahepatic ducts accompanied by emergence of the main papillary retraction

The patient was a 25-year-old man with a diagnosis of Crohn's disease since 1997 (Patient 4 in our previous study) (6). An asymptomatic increase in liver enzymes was noticed in 2000. On July 2004, endoscopic cholangiography showed involvement of only the intrahepatic bile ducts and normal appearing main papilla. Endoscopic sphincterotomy was performed. On November 2009, involvement of the extrahepatic bile ducts (Figure 2a) and retraction of the main papilla became apparent (Figure 2b).




Figure 2. a, b. PSC progressed to extrahepatic bile ducts 5.5 years after involvement of the intrahepatic bile ducts (a). Retraction of the main papilla became apparent with the involvement of the extrahepatic bile ducts (b).

Case 3: Retraction of the naïve papilla

A 36-year-old woman with ulcerative colitis presented with itching. Asymptomatic increase in liver enzymes had been noticed within the last 3 years. Endoscopic cholangiography showed involvement of both of the intra and extrahepatic bile ducts (Figure 3a). Endoscopy showed a naïve papilla which appeared to be retracted away from the duodenal lumen toward the biliary system (Figure 3b).




Figure 3. a, b. Endoscopic cholangiography showing involvement of both the intra and extrahepatic bile ducts in a PSC patient with naïve papilla (a). Endoscopy showed retraction of the main papilla (b).

Case 4: Emergence of main papillary retraction detected via MRCP

A 47-year-old man underwent MRCP on October 2006 because of asymptomatic increase in liver enzymes in the last one year. Intra and extrahepatic bile ducts were involved and the main papilla was normal (Figure 4a). A diagnosis of PSC was made. Endoscopic cholangiography was not performed because of the asymptomatic course. The patient was admitted with itching, jaundice, abdominal pain and fever in 2009. MRCP demonstrated retraction of the main papilla toward the biliary system at this time (Figure 4b).




Figure 4. a, b. Normal papilla of a patient with PSC (a). MRCP showed tent-like retraction of the main papilla (arrow) 4 years later (b).

DISCUSSION

This case series shows that retraction of the main papilla toward the biliary system can develop as the PSC progresses regardless of the presence of a sphincterotomy history. Depending on the degree of retraction, the duodenal wall around the papilla can also be retracted which results in a tent-like appearance. Main papillary retraction was not encountered in the absence of extrahepatic bile duct involvement and could be diagnosed by MRCP.

Retraction of the main papilla was observed in two patients with naïve papillae. In our previous series including 10 patients with PSC, all of the 7 patients with main papillary retraction had previously undergone endoscopic sphincterotomy (6). This confusion was the main underlying reason for the present study (7). It is not surprising that most of the PSC patients with main papillary retraction had a history of sphincterotomy because symptomatic dominant strictures are common and require sphincterotomy. Another issue is that the main papillary retraction appears to develop slowly over a number of years. Retraction of the main papilla was first seen 4.5 and 5.5 years after sphincterotomy (Patients 1 and 2), and 3 and 3.5 years after the first detection of increased liver enzymes in patients with naïve papillae (Patients 3 and 4). The mean time elapsed from the first detection of elevated liver enzymes to the appearance of main papillary retraction was 4.1 years (range: 3-5.5 years). This was comparable to the corresponding number of 5.1 years (range: 2-7 years) in our previous series (6).

In patients with PSC, retraction of the main papilla and surrounding duodenal wall takes time. PSC is a progressive disease (4). Dominant strictures of the common or main hepatic ducts are seen in approximately half of the patients (3,8,9). We think that the progressive bile duct fibrosis leads to shortening of the ducts and results in retraction of the main papilla toward the biliary system.

Involvement of only the intrahepatic bile ducts was not accompanied by retraction of the main papilla (Case 2). Five years later, PSC progressed to the extrahepatic bile ducts and the papilla was retracted (Figure 2). This was consistent with the findings of our previous study which showed that main papillary retraction was not encountered unless there was extrahepatic involvement (6). Collectively, these findings suggest that the emergence of the main papillary retraction depends on the involvement of the extrahepatic bile ducts but this hypothesis needs to be supported in larger series.

The capacity of MRCP to show retraction of the main papilla provides a valuable alternative to endoscopy. The air that is introduced into the gastrointestinal lumen during endoscopy inflates the duodenum. As a result, the retracted position of the main papilla becomes less apparent. Another benefit of MRCP is that it avoids the possibility of the papilla being pushed artificially into a retracted position due to the force exerted by

the ERCP catheter. We think that retraction of the main papilla can be included among the diagnostic criteria of PSC via MRCP.

The detection of main papillary retraction appears to be useful in the differential diagnosis of PSC. Kubota et al. showed that the finding of a retracted papilla could be used in distinguishing PSC from sclerosing cholangitis caused by autoimmune pancreatitis. Papilla was enlarged in patients with the autoimmune disease whereas retracted in those with PSC (10).

Endoscopic therapy of PSC becomes more difficult in patients who have a retracted main papilla. According to the severity of the retraction, the distance between the papilla and the tip of the inserted endoscope lengthens, and the stent placement requires a much more effort. In patients with PSC, cholangitis is a frequent complication of ERCP therefore we recommend that contrast material should be given only to the patients in whom selective biliary cannulation has been achieved (2).

In conclusion, retraction of the main papilla in PSC can be seen regardless of the presence of a prior sphincterotomy history and MRCP can be used to detect this condition. Studies about the sensitivity and specificity of magnetic resonance cholangiography in the detection of main papillary retraction and direct observation of the retraction of the papilla at autopsy or explanted livers of patients with PSC are subjects of future research.

Conflict of Interest: No conflict of interest was declared by the authors.

REFERENCES

1. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. *Hepatology* 2010; 51: 660-78.
2. Bangarulingam SY, Gossard AA, Petersen BT, et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. *Am J Gastroenterol* 2009; 104: 855-60.
3. Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. *Am J Gastroenterol* 2007; 102: 107-14.
4. Porayko MK, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis: a progressive disease? *Semin Liver Dis* 1991; 11: 18-25.
5. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. *Hepatology* 2006; 44: 1063-74.
6. Parlak E, Cicek B, Disibeyaz S, et al. Endoscopic findings with primary sclerosing cholangitis: retraction of the main duodenal papilla into the duodenal wall. *Gastrointest Endosc* 2007; 65: 532-6.
7. Dumonceau JM. Biliary endoscopic retrograde cholangiopancreatography. *Endoscopy* 2010; 42: 58-61.
8. Bjornsson E, Lindqvist-Ottosson J, Asztely M, et al. Dominant strictures in patients with primary sclerosing cholangitis. *Am J Gastroenterol* 2004; 99: 502-8.
9. Rudolph G, Gotthardt D, Kloters-Plachky P, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. *J Hepatol* 2009; 51: 149-55.
10. Kubota K, Kato S, Akiyama T, et al. Differentiating sclerosing cholangitis caused by autoimmune pancreatitis and primary sclerosing cholangitis according to endoscopic duodenal papillary features. *Gastrointest Endosc* 2008; 68: 1204-8.

A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B

Ümit Bilge Doğan¹, Agah Bahadır Öztürk², Mustafa Salih Akın¹, Serkan Yalaki¹, Murat Sayan³

¹Department of Gastroenterology, Adana Numune Training and Research Hospital, Adana, Turkey

²Department of Family Medicine, Adana Numune Training and Research Hospital, Adana, Turkey

³Department of Clinical Laboratory, Kocaeli University Medical Faculty Hospital, Kocaeli, Turkey

ABSTRACT

Entecavir (ETV) is a potent nucleoside analogue against hepatitis B virus (HBV), and the emergence of drug resistance is rare in nucleoside-naive patients because development of ETV resistance (ETVr) requires at least three amino acid substitutions in HBV reverse transcriptase. We observed a case of genotypic ETVr with viral and biochemical breakthrough during ETV treatment of nucleoside-naive patients with chronic hepatitis B (CHB). A 57-years-old HBeAg-positive man received ETV 0.5 mg/day for 145 weeks. HBV DNA was 7.7 log₁₀ copies/ml at baseline, decreased to below 2 at week 48, declined to a nadir of 0 (negative) at week 72, and rebounded to 2.2 log₁₀ copies/ml at week 90 and remained this level until 109 weeks and increased to 6.8 log₁₀ copies/ml at week 145. Alanine aminotransferase (ALT) level increased to 440 IU/L at week 145. The ETVr-related substitution (rtS202P) and lamivudine resistance-related substitutions (rtL180M + rtM204V) were detected by DNA sequencing analysis at week 145. The patient discontinued ETV therapy at week 145, and then received 245 mg of tenofovir disoproxil fumarate (TDF). Afterwards, HBV DNA level dropped to below 2.6 log₁₀ copies/ml and ALT level was normalized after 19 weeks of TDF dosing. The three substitutions associated with ETV and lamivudine resistance developed after complete viral suppression in a nucleoside-naive CHB patient during ETV treatment. In spite of the extremely rare chance of viral mutation during ETV treatment, nucleoside-naive patients should be carefully monitored for resistance even if complete suppression is present.

Keywords: Entecavir, chronic hepatitis b, drug resistance, nucleoside-naive

INTRODUCTION

Approximately 400 million people worldwide have chronic hepatitis B virus (HBV) infections, with a risk for chronic, life-threatening liver disease (1). Antiviral therapy for HBV can provide suppression of viral replication and halt disease progression (2,3). However, therapeutic benefits are diminished with the emergence of drug-resistant virus, which occurs most often with prolonged therapy and incomplete viral suppression (4).

Resistance to nucleoside/nucleotide antivirals arises through substitutions in the HBV polymerase (*pol*) reverse transcriptase domain (RT) that arise spontaneously through low-fidelity replication and are enriched through drug-selective pressure (2,3). Antiviral therapies are characterized by their barrier to resistance, which includes three components: (1) the potency of

the antiviral in suppressing viral replication, (2) a "genetic barrier", i.e., the number of genetic changes required to effectively reduce drug susceptibility that results in virologic breakthrough, and (3) the replication fitness of the resistant virus. For lamivudine (LVD), adefovir-dipivoxil (ADV), and telbivudine (LdT), the genetic barrier to resistance in antiviral-naive patients can be as low as a single substitution. So, developments of resistance of these drugs are higher.

Several factors contribute to the high barrier to resistance with entecavir (ETV). ETV is potent, resulting in a higher proportion of patients achieving undetectable HBV DNA than those treated with LVD (5,6) or ADV (7). Marked reductions in ETV susceptibility require substitutions at residues rtT184, rtS202, or rtM250 in LVD resistance (LVD_r) HBV with changes at rtM204I/V ± rtL180M

Address for Correspondence: Ümit Bilge Doğan, Department of Gastroenterology, Adana Numune Training and Research Hospital, Adana, Turkey
E-mail: ubdogan@hotmail.com

Received: May 08, 2012

Accepted: November 28, 2012

© Copyright 2014 by The Turkish Society of Gastroenterology • Available online at www.turkjgastroenterol.org • DOI: 10.5152/tjg.2014.3605

(8,9). Thus, the *genetic* barrier to ETV resistance (ETVr) involves multiple substitutions. In-vitro studies demonstrated that the highest levels of phenotypic resistance, leading to virologic breakthrough, require both the rtM204V and rtL180M LVDr substitutions with at least one ETVr substitution (8,10). Additionally, ETVr HBV exhibits impaired replication fitness (9). Thus, the finding that ETVr has been rarely observed in nucleoside-naive patients (11,12) is likely due to a combination of a high genetic barrier, potent viral suppression, and reduced fitness of resistant viruses.

So, it has been reported that the development of ETVr in nucleoside-naive patients is very rare, even after 5 years of therapy (13). Recently, however, rare cases of ETVr, which developed in nucleoside-naive patients, have been reported (14-16). We also observed one patient who developed ETVr-associated HBV RT substitutions, followed by virologic and biochemical breakthrough after complete viral suppression in longterm ETV treatment of nucleoside-naive CHB patients. In this study, we report this case in detail.

CASE REPORT

A 57-years-old Turkish man with CHB received a checkup in April 2009, and was found to be seropositive for hepatitis B surface antigen (HBsAg) with normal liver enzymes. He has a history of asthma and use of inhaling corticosteroids for 9 years. He didn't drink and smoke. Hepatitis B e antigen (HBeAg) was positive and serum HBV DNA was 7.7 log₁₀ copies/mL (Cobas AmpliPrep-Taqman HBV Test, Roche Diagnostics, Mannheim, Germany). Other baseline characteristics are shown in Table 1.

He was diagnosed with CHB by percutaneous liver biopsy (mild activity [7] and severe fibrosis [F3], according to Knodell score) at another hospital in May 2009. At this time, treatment with ETV was started at 0.5 mg/day. After the start of ETV, the serum HBV DNA level decreased to below 2 log₁₀ copies/ml at week 48 and declined to a nadir of 0 copies/ml at week 72 of ETV treatment. Thereafter, HBV DNA level rebounded to 2.2 log₁₀ copies/ml at week 90 and remained this level until 109 weeks and increased to 6.8 log₁₀ copies/ml at week 145. ALT levels increased from 19 IU/L at week 122 to 440 IU/L at week 145. The patient discontinued ETV therapy at week 145, and then received 245 mg of tenofovir disoproxil fumarate (TDF). Afterwards, HBV DNA level dropped to below 2.6 log₁₀ copies/ml and ALT level was normalized after 19 weeks of TDF dosing (Figure 1).

A pair of primers was designed (forward: 5'-TC-GTGGTG-GACTTCTCTCAATT-3' and reverse: 5'-CGTTGA-CAGACTTTC-CAATCAAT-3') for amplification of the HBV *pol* region for the analysis of HBV drug resistance. PCR conditions were 95°C for 15 min, followed by 45 cycles consisting of 95°C for 45 s, 56°C for 45 s, and 72°C for 45 s. The final primer concentration was 0.3 μM, and the HBV amplicon size was 742 bp. All PCR products were purified using the High Pure PCR Product Purification Kit (Roche Diagnostics GmbH, Mannheim, Germany) and

directly sequenced on ABI PRISM 310 Genetic Analyzer equipment using the DYEnamic ET Terminator Cycle Sequencing Kit (Amersham Pharmacia Biotech Inc., Piscataway, USA). For cycle sequencing, we used the following thermal protocol: 35 cycles consisting of 95°C for 20 s, 50°C for 25 s, and finally 60°C for 2 min. The reverse primer was used as the sequencing primer at a final concentration of 0.5 μM. Electropherogram-obtained sequences were assembled using Vector NTI v5.1 (InforMax, Invitrogen Life Science Software, Frederick, MD, USA).

Table 1. Baseline characteristics of patient

	Normal range	Unit	Case
Age	-	-	57
Gender	-	-	Male
Fasting blood glucose	74-106	mg/dL	104
Blood Urea Nitrogen	6-20	mg/dL	12
Creatine	0-0.9	mg/dL	0.9
Aspartate Aminotransferase	0-31	IU/L	28
ALT	0-33	IU/L	31
Alkaline Phosphatase	0-98	IU/L	78
GGT	0-36	IU/L	103
T. Bil	0-1.1	mg/dL	1.3
Albumin	3.5-5.2	g/dL	4.7
Hb	123-153	g/dL	15
WBC	4.4-11.3	103/μ	7.5
Plt	136-380	103/μ	145
Prothrombin time	12-15	second	13.8
INR	0.8-1.2	-	1.18
AFP	0-5.8	ng/ml	14
ANA	Negative	-	Negative
AMA	Negative	-	Negative
SMA	Negative	-	Negative
HBsAg	0-0.9	IU/mL	250 (Positive)
HBeAg	0-1	S/CO	18.7 (Positive)
Anti-HBe	0-50	S/CO	1.8 (Negative)
Anti-HBs	0-10	IU/mL	0 (Negative)
Anti-HCV	0-0.9	IU/mL	0 (Negative)
Anti-Delta	Negative	IU/mL	Negative
HBV DNA (PCR)	Negative	Log ₁₀ copies/mL	7.7
HBV genotype	-	-	D
HBV subgenotype	-	-	D2
Liver histology	Normal	-	HAI 7, F 3 (Knodell)

INR: International normalized ratio; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCV: hepatitis C virus; PCR: polymerase chain reaction; ALT: alanine Aminotransferase; GGT: gamma-glutamyl transpeptidase; T. Bil: total bilirubine; Hb: hemoglobine; WBC: white blood cells; AFP: alpha-fetoprotein; ANA: anti-nuclear antibody; AMA: anti-mitochondrial antibody; ASMA: anti-smooth muscle antibody




Figure 1. Clinical course of case.

The LVDr-related substitutions rtL180M and rtM204V, as well as ETVr-related substitution rtS202G, were detected at week 145.

DISCUSSION

Treatment of CHB has evolved markedly with the introduction of nucleoside-analogue antivirals, that is, LVD, ADV, ETV, and LdT, to clinical practice. The most important limitation of long-term nucleoside analogue treatment for CHB is the emergence of drug resistant mutations in HBV followed by viral breakthrough and hepatitis flare (3). The most common mutation associated with LVDr involves substitution of methionine in the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the HBV DNA *pol* gene RT domain with valine or isoleucine (rtM204V/I), with or without a leucine-to-methionine substitution in an upstream region (rtL180M) (17). It was reported that LVDr was detected at a rate of 14 to 32% after 1 year and 60 to 70% after 5 years of LVD treatment (3). LdT resistance also arises at the YMDD motif and has been reported in the context of virologic breakthrough, at 22% and 9% over 2 years in patients who are positive and negative, respectively, for the hepatitis B e antigen (11,12). The substitutions conferring resistance to ADV are asparagine to threonine (rtN236T) and alanine to valine or threonine (rtA181V/T) (20), and the cumulative probability of ADV resistance with elevation of HBV DNA level has been reported to be 20% at 5 years in HBeAg-negative patients (21) and as high as 42% in HBeAg-positive patients (22).

Entecavir displays several properties for consideration as the first-line nucleoside analogue because of its potent antiviral activity and a lower frequency of drug resistance than LVD, ADV, or LdT (23). In the case of ETV, it has been reported that resistance to the drug requires at least one of three substitutions in HBV RT, that is, rtT184, rtS202, and rtM250, as well as LVDr-related substitutions rtL180M and rtM204V (24).

There is a high genetic barrier to resistance to ETV in nucleoside-naïve patients and <1% experience virologic breakthrough with ETVr through 5 years of therapy (13). In that study, ETVr substitutions were detected in only three nucleoside-naïve patients (3 of 663). Two of these patients with wild-type virus at baseline developed rtM204V+rtL180M and rtS202G simultaneously. They did not achieve undetectable HBV-DNA (<300 copies/mL) on ETV. Only HBeAg-negative one patient with the rtM204I substitution achieved undetectable HBV DNA (<300 copies/mL) in that study. So, it was concluded that, ETVr changes combined with only the rtM204I LVDr substitutions displayed lower levels of phenotypic ETV resistance (25).

The results of a parallel survey of surveillance conducted in Japan in which nucleoside-naïve patients received the 0.5 mg dosage of ETV for 3 years yielded only one of 66 patients who developed genotypic resistance (1.7%) (12).

Simultaneous emergence of all three resistance substitutions has been noted in other reports of ETVr.(14). In that report, ETVr developed in a nucleoside-naïve patient with genotype H of HBV, which did not achieve undetectable HBV DNA levels. In another report, ETVr have been emerged in two Japanese nucleoside-naïve CHB patients after prolonged therapy and incomplete suppression (15). Finally, in a recent report, the three substitutions associated with ETV and LVD resistance has been developed simultaneously without complete suppression in a nucleoside-naïve CHB patient after extended therapy (16).

Entecavir resistance has been attributed to high pretreatment viral loads and persistently detectable HBV-DNA by PCR during the treatment course in all reports of ETVr. It is believed that some subpopulations of HBV that proliferate very actively and are not completely suppressed by ETV may have a chance of

being selected for the resistance substitutions required for ETV virologic failure. Phenotypic analyses of samples associated with virologic breakthrough confirmed that ETV susceptibility correlates with the spectrum of these additional substitutions conferring genotypic resistance and the increased level of circulating HBV DNA (25). Thus, all of the ETVr cases had incomplete viral suppression except one HBeAg-negative patient presented in the study of Tenney et al (13). Our patient also had complete viral suppression before the development of ETVr. The three substitutions associated with ETV and LVD resistance developed after complete viral suppression. So, circulating HBV DNA could not a reason for ETVr. We could not perform DNA sequence analysis before the HBV treatment. So we dont know whether baseline rtM204I substitution was present or not as in the study of Tenney et al (13).

CONCLUSION

In this article, we report a case with confirmed genotypic resistance to ETV, virologic and biochemical breakthrough during long-term ETV treatment for nucleoside-naïve CHB patients. The present case of ETV resistance is particularly notable for its emergence in a case with complete viral suppression, which is rare. To our knowledge, this is the second report of emerging resistance to ETV in a nucleoside-naïve patient after complete viral suppression. In spite of the extremely rare chance of viral mutation during ETV treatment, nucleoside-naïve patients should be carefully monitored for resistance even if complete suppression is present.

Conflict of Interest: No conflict of interest was declared by the authors.

REFERENCES

- Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. *Epidemiol Rev* 2006; 28: 112-25.
- Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. *Gastroenterology* 2008; 134: 405-15.
- Lok A, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; 45: 507-39.
- Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. *Hepatology* 2000; 32: 866-7.
- Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med* 2006; 354: 1011-20.
- Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2006; 354: 1001-10.
- Leung N, Peng C-Y, Sollano L, et al. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naïve adults: 24 wk results (E.A.R.L.Y. Study). *Hepatology* 2006; 44 (4 Suppl. 1): 554A.
- Baldick CJ, Eggers BJ, Fang J, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. *J Hepatol* 2008; 48: 895-902.
- Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. *Hepatology* 2008; 47: 1473-82.
- Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. *Antimicrob Agents Chemother* 2007; 51: 902-11.
- Colonna RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. *Hepatology* 2006; 44: 1656-65.
- Yokosuka O, Kumada H, Toyota J, et al. Three year assessment of entecavir (ETV) resistance in nucleoside naïve and lamivudine (LVD) refractory Japanese patients with chronic hepatitis B (CHB). *Hepatol Int* 2008; 2: A161.
- Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows Hepatitis B Virus Resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology* 2009; 49: 1503-14.
- Suzuki F, Akuta N, Suzuki Y, et al. Selection of a virus strain resistant to entecavir in a nucleoside-naïve patient with hepatitis B of genotype H. *J Clin Virol* 2007; 39: 149-52.
- Kobashi H, Fujioka S, Kawaguchi M, et al. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naïve chronic hepatitis B. *Hepatol Int*. 2009; 3: 403-10.
- Lee HW, Kim HJ, Hong SP, et al. Simultaneous Emergence of Entecavir Resistance Mutations in a Nucleoside-Naïve Chronic Hepatitis B Patient. *Intervirology* 2012; 55: 3804.
- Lai CL, Chien RN, Leung NW, et al. A one year trial of lamivudine for chronic hepatitis B. *N Engl J Med* 1998; 339: 61-8.
- Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. *Hepatology* 2006; 44: 222A.
- Strand DN, Seifer M, Patty A, et al. HBV resistance determination from the telbivudine globe registration trial. *J Hepatol* 2006; 44: S191.
- Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. *Gastroenterology* 2003; 125: 292-7.
- Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir Dipivoxil 438 Study Group. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. *Gastroenterology* 2006; 131: 1743-51.
- Hepsera (Adefovir dipivoxil) current US package insert. CA: Gilead Sciences. p. 3
- Keefe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. *Clin Gastroenterol Hepatol* 2006; 4: 936-62.
- Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. *Antimicrob Agents Chemother* 2004; 48: 3498-507.
- Baldick CJ, Eggers BJ, Fang J, et al. Hepatitis B virus quasi-species susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. *J Hepatol* 2008; 48: 895-902.